Title Page
Contents
ABSTRACT 9
Ⅰ. Introduction 11
Ⅱ. Material and methods 15
2.1. Generation of hiPSC-CMs 15
2.2. Preparation of reagents 16
2.3. Cell viability assay 16
2.4. Seeding of hiPSC-CMs on MEA plate 17
2.5. Measurement of field potential and contractility 18
2.6. Statistical analysis 19
Ⅲ. Results 20
3.1. Cell viability test of hiPSC-CMs according to treatment of bisphenols 20
3.2. FP analysis of hiPSC-CMs according to treatment of BPA 22
3.3. FP analysis of hiPSC-CMs according to treatment of bisphenol analogues 28
3.4. Contractility analysis of hiPSC-CMs according to treatment of bisphenols 32
Ⅳ. Discussion 39
References 44
Abstract (in Korean) 46
Tale 1. FP measurement of reference drugs and bisphenols. 28
Tale 2. Contractility measurement of reference drugs and bisphenols. 38
Figure 1. Schematic diagram for cardiotoxicity evaluation and verification of survival rate in hiPSC-CMs following Bisphenol analogues treatment. 21
Figure 2. MEA-based dual-cardiotoxicity evaluation methods for measuring cardiotoxicity induced by Bisphenol treatment and FP changes in BPA and... 25
Figure 3. Comparison of changes in FP of hiPSC-CMs according to Bisphenol analogues treatment. 30
Figure 4. Comparison of changes in contractility of hiPSC-CMs according to reference drugs and Bisphenol analogues treatment. 34
Supplementary Figure 1. Raw waveform of MEA-based contractility in hiPSC- CMs according to treatment of 100μM BPA, 0.1 μM nifedipine, and 0.1 μM E-4301. 36